EP3 prostanoid receptor isoforms utilize distinct mechanisms to regulate ERK 1/2 activation

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1791, Issue 4, 2009, Pages 238-245

  Israel, Davelene D ^a   Regan, John W ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

E Prostanoid receptor; Epidermal growth factor receptor; ERK 1 2; Phosphoinositide 3 kinase; Prostaglandin E2; Protein kinase C

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E2; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ELK 1; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL;

CELLS, CULTURED; CYCLIC AMP; ENZYME ACTIVATION; ETS-DOMAIN PROTEIN ELK-1; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOBLOTTING; KIDNEY; LUCIFERASES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTEIN ISOFORMS; RADIOLIGAND ASSAY; RECEPTORS, PROSTAGLANDIN E; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC;

EID: 62249100641     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2009.01.021     Document Type: Article

References (35)

1. Breyer R.M., Bagdassarian C.K., Myers S.A., and Breyer M.D. Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 661-690
2. Fujino H., and Regan J.W. EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol. Pharmacol. 69 (2006) 5-10
3. Regan J.W., Bailey T.J., Donello J.E., Pierce K.L., Pepperl D.J., Zhang D., Kedzie K.M., Fairbairn C.E., Bogardus A.M., Woodward D.F., et al. Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini. Br. J. Pharmacol. 112 (1994) 377-385
4. Schmid A., Thierauch K.-H., Schleuning W.-D., and Dinter H. Splice variants of the human EP3 receptor for prostaglandin E2. Eur. J. Biochem. 228 (1995) 23-30
5. Kotani M., Tanaka I., Ogawa Y., Usui T., Mori K., Ichikawa A., Narumiya S., Yoshimi T., and Nakao K. Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol. Pharmacol. 48 (1995) 869-879
6. Kotelevets L., Foudi N., Louedec L., Couvelard A., Chastre E., and Norel X. A new mRNA splice variant coding for the human EP3-I receptor isoform, prostaglandins. Leukot. Essent. Fat. Acids 77 (2007) 195-201
7. An S., Yang J., So S.W., Zeng L., and Goetzl E.J. Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry 33 (1994) 14496-14502
8. Jin J., Mao G.F., and Ashby B. Constitutive activity of human prostaglandin E receptor EP3 isoforms. Br. J. Pharmacol. 121 (1997) 317-323
9. Bilson H.A., Mitchell D.L., and Ashby B. Human prostaglandin EP3 receptor isoforms show different agonist-induced internalization patterns. FEBS Lett. 572 (2004) 271-275
10. Burkey T.H., and Regan J.W. Activation of mitogen-activated protein kinase by the human prostaglandin EP3A receptor. Biochem. Biophys. Res. Commun. 211 (1995) 152-158
11. Kotani M., Tanaka I., Ogawa Y., Suganami T., Matsumoto T., Muro S., Yamamoto Y., Sugawara A., Yoshimasa Y., Sagawa N., Narumiya S., and Nakao K. Multiple signal transduction pathways through two prostaglandin E receptor EP3 subtype isoforms expressed in human uterus. J. Clin. Endocrinol. Metab. 85 (2000) 4315-4322
12. Ushikubi F., Segi E., Sugimoto Y., Murata T., Matsuoka T., Kobayashi T., Hizaki H., Tuboi K., Katsuyama M., Ichikawa A., Tanaka T., Yoshida N., and Narumiya S. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395 (1998) 281-284
13. Takeuchi K., Ukawa H., Kato S., Furukawa O., Araki H., Sugimoto Y., Ichikawa A., Ushikubi F., and Narumiya S. Impaired duodenal bicarbonate secretion and mucosal integrity in mice lacking prostaglandin E-receptor subtype EP(3). Gastroenterology 117 (1999) 1128-1135
14. Qian Y.M., Jones R.L., Chan K.M., Stock A.I., and Ho J.K. Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery. Br. J. Pharmacol. 113 (1994) 369-374
15. Konger R.L., Malaviya R., and Pentland A.P. Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes. Biochim. Biophys. Acta 1401 (1998) 221-234
16. Richards J.A., and Brueggemeier R.W. Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J. Clin. Endocrinol. Metab. 88 (2003) 2810-2816
17. Konger R.L., Brouxhon S., Partillo S., VanBuskirk J., and Pentland A.P. The EP3 receptor stimulates ceramide and diacylglycerol release and inhibits growth of primary keratinocytes. Exp. Dermatol. 14 (2005) 914-922
18. Kotani M., Tanaka I., Ogawa Y., Usui T., Tamura N., Mori K., Narumiya S., Yoshimi T., and Nakao K. Structural organization of the human prostaglandin EP3 receptor subtype gene (PTGER3). Genomics 40 (1997) 425-434
19. Shoji Y., Takahashi M., Takasuka N., Niho N., Kitamura T., Sato H., Maruyama T., Sugimoto Y., Narumiya S., Sugimura T., and Wakabayashi K. Prostaglandin E receptor EP3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis. Carcinogenesis 26 (2005) 2116-2122
20. Sanchez T., and Moreno J.J. GR 63799X, an EP3 receptor agonist, induced S phase arrest and 3T6 fibroblast growth inhibition. Eur. J. Pharmacol. 529 (2006) 16-23
21. Hashimoto N., Watanabe T., Ikeda Y., Yamada H., Taniguchi S., Mitsui H., and Kurokawa K. Prostaglandins induce proliferation of rat hepatocytes through a prostaglandin E2 receptor EP3 subtype. Am. J. Physiol. 272 (1997) G597-604
22. Chuang P.C., Sun H.S., Chen T.M., and Tsai S.J. Prostaglandin E2 induces fibroblast growth facto 9 via EP3-dependent protein kinase Cdelta and Elk-1 signaling. Mol. Cell. Biol. 26 (2006) 8281-8292
23. Yamaki T., Endoh K., Miyahara M., Nagamine I., Thi Thu Huong N., Sakurai H., Pokorny J., and Yano T. Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3. Cancer Lett. 214 (2004) 115-120
24. Cobb M.H., Hepler J.E., Cheng M., and Robbins D. The mitogen-activated protein kinases, ERK1 and ERK2. Semin. Cancer Biol. 5 (1994) 261-268
25. Werry T.D., Christopoulos A., and Sexton P.M. Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. Curr. Pharm. Des. 12 (2006) 1683-1702
26. Werry T.D., Sexton P.M., and Christopoulos A. "Ins and outs" of seven-transmembrane receptor signalling to ERK. Trends Endocrinol. Metab.: TEM 16 (2005) 26-33
27. Treinies I., Paterson H.F., Hooper S., Wilson R., and Marshall C.J. Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal to stimulate DNA synthesis. Mol. Cell. Biol. 19 (1999) 321-329
28. Gille H., Kortenjann M., Thomae O., Moomaw C., Slaughter C., Cobb M.H., and Shaw P.E. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J. 14 (1995) 951-962
29. Murakami M., Ui M., and Iba H. Fra-2-positive autoregulatory loop triggered by mitogen-activated protein kinase (MAPK) and Fra-2 phosphorylation sites by MAPK. Cell Growth Differ. 10 (1999) 333-342
30. Treisman R. Regulation of transcription by MAP kinase cascades. Current Opin. Cell. Biol. 8 (1996) 205-215
31. Gao Y., Tang S., Zhou S., and Ware J.A. The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor. J. Pharmacol. Exp. Ther. 296 (2001) 426-433
32. Howe L.R., and Marshall C.J. Lysophosphatidic acid stimulates mitogen-activated protein kinase activation via a G-protein-coupled pathway requiring p21ras and p74raf-1. J. Biol. Chem. 268 (1993) 20717-20720
33. Kue P.F., Taub J.S., Harrington L.B., Polakiewicz R.D., Ullrich A., and Daaka Y. Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells. Int. J. Cancer 102 (2002) 572-579
34. Vial E., and Marshall C.J. Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J. Cell Sci. 116 (2003) 4957-4963
35. Ebisuya M., Kondoh K., and Nishida E. The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity. J. Cell Sci. 118 (2005) 2997-3002